tgtherapeutics.comInvestor Relations TG Therapeutics Inc
tgtherapeutics.com Profile
tgtherapeutics.com
Sub Domains:ir.tgtherapeutics.com
Title:Investor Relations TG Therapeutics Inc
Description：TG Therapeutics is a biopharmaceutical company focused on the acquisition development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases Currently the company is developing two therapies targeting hematological malignancies and autoimmune diseases Ublituximab TG-1101 is a novel glycoengineered
Discover tgtherapeutics.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
tgtherapeutics.com Information
| Website / Domain: | tgtherapeutics.com |
| HomePage size: | 82.151 KB |
| Page Load Time: | 0.757204 Seconds |
| Website IP Address: | 155.130.138.22 |
| Isp Server: | Weyerhaeuser Company |
tgtherapeutics.com Ip Information
| Ip Country: | United States |
| City Name: | Federal Way |
| Latitude: | 47.309940338135 |
| Longitude: | -122.31390380859 |
tgtherapeutics.com Keywords accounting
| Keyword | Count |
|---|
tgtherapeutics.com Httpheader
| Server: nginx |
| Date: Wed, 19 Aug 2020 13:05:16 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| X-Powered-By: PHP/7.3.21, PleskLin |
| Link: https://www.tgtherapeutics.com/wp-json/; rel="https://api.w.org/", https://www.tgtherapeutics.com/; rel=shortlink |
| Vary: Accept-Encoding,User-Agent |
| Content-Encoding: gzip |
tgtherapeutics.com Meta Info
| charset="utf-8"/ |
| content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport"/ |
| content="telephone=no" name="format-detection"/ |
| content="WordPress 5.4.2" name="generator" |
| content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress." name="generator" |
| content="https://www.tgtherapeutics.com/wp-content/uploads/2020/02/TG_Icon.svg" name="msapplication-TileImage"/ |
155.130.138.22 Domains
| Domain | WebSite Title |
|---|
tgtherapeutics.com Similar Website
| Domain | WebSite Title |
|---|---|
| Investor Relations TG Therapeutics Inc | |
| Investor Relations | TG Therapeutics, Inc. | |
| Investor Relations - Revance Therapeutics, Inc. | |
| Investor Overview | Mateon Therapeutics | |
| INVESTOR OVERVIEW Insys Therapeutics Inc | |
| Investor Overview | Mateon Therapeutics | |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) | |
| Nelnet Inc - Investor Resources - Investor Services Program | |
| Exantas Investor Relations - Investor Overview | |
| Winnebago Investor Relations Investor Home | |
| Spark Therapeutics | |
| About Us | Nektar Therapeutics | |
| United Therapeutics | |
| Investors | PTC Therapeutics, Inc. | |
| Careers | Ebb Therapeutics |
tgtherapeutics.com Traffic Sources Chart
tgtherapeutics.com Alexa Rank History Chart
tgtherapeutics.com Html To Plain Text
ABOUT US Our Story Message From Our CEO Our Leadership Our Board OUR SCIENCE Our Approach Therapeutic Focus Work With Us OUR PIPELINE Overview Ublituximab Umbralisib TG-1501 TG-1701 TG-1801 OUR PUBLICATIONS OUR TRIALS Overview Pivotal Trials Expanded Access Policy INVESTORS & MEDIA Press Releases Stock Information Historic Stock Lookup Sec Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Our Leadership Corporate Governance Faqs Mobile Menu Mobile Close ABOUT US Our Story Message From Our CEO Our Leadership Our Board OUR SCIENCE Our Approach Therapeutic Focus Work With Us OUR PIPELINE Overview Ublituximab Umbralisib TG-1501 TG-1701 TG-1801 OUR PUBLICATIONS OUR TRIALS Overview Pivotal Trials Expanded Access Policy INVESTORS & MEDIA Press Releases Stock Information Historic Stock Lookup Sec Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Our Leadership Corporate Governance Faqs Search -- A Powerful New Future in Cellular IO " onClick="ga('send', 'event', { eventCategory: 'Homepage', eventAction: 'Click', eventLabel: 'News'});" BELLICUM ® is engineering high-performance cellular immunotherapies and unleashing their power against a wide range of cancers, impacting more patients than ever. -- -- FIERCELY FOCUSED on the development of novel treatments for patients with B-cell malignancies and autoimmune diseases. Learn about us Explore our pipeline investor Information Read our publications Latest News Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and Read More > Read More Read More -- -- class="content" -- -- 2 Gansevoort Street, 9th Floor New York, NY 10014 Email Us (212) 554-4484 © 2020. All rights reserved. Join Us CONTACT US PRIVACY POLICY Terms of Use Join us Contact Us Privacy Policy Terms of Use -- --...
tgtherapeutics.com Whois
"domain_name": "TGTHERAPEUTICS.COM",
"registrar": "Network Solutions, LLC",
"whois_server": "whois.networksolutions.com",
"referral_url": null,
"updated_date": [
"2019-10-07 08:07:10",
"2019-10-07 08:16:02"
],
"creation_date": "2011-12-06 14:57:45",
"expiration_date": "2020-12-06 14:57:45",
"name_servers": [
"NS47.WORLDNIC.COM",
"NS48.WORLDNIC.COM"
],
"status": "clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"emails": [
"abuse@web.com",
"wy7uz2jm7bc@networksolutionsprivateregistration.com"
],
"dnssec": "unsigned",
"name": "PERFECT PRIVACY, LLC",
"org": null,
"address": "5335 Gate Parkway care of Network Solutions PO Box 459",
"city": "Jacksonville",
"state": "FL",
"zipcode": "32256",
"country": "US"